Skip to content
Sign in

IONS · NASDAQ

Ionis Pharmaceuticals (IONS) Stock Price & Fundamentals

$244.31+1.05%+$2.54End-of-day price as of Oct 9, 2026

Ionis Pharmaceuticals (IONS) closed at $244.31 on Oct 9, 2026, up 1.05% from the previous close of $241.77.

Share price, past year

1Y −4.97%

52-week range $217.51 – $261.00. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$244.31
Sep 30, 2026$229.14
Aug 31, 2026$222.44
Jul 31, 2026$231.45
Jun 30, 2026$240.68
May 29, 2026$244.88
Apr 30, 2026$246.33
Mar 31, 2026$238.27
Feb 27, 2026$235.06
Jan 30, 2026$242.19
Dec 31, 2025$246.91
Nov 28, 2025$245.40
Oct 31, 2025$239.68

Key statistics

Market cap
$40.47B
P/E (TTM)
—
EPS (TTM)
−$3.46
Revenue (TTM)
$874.09M
Net income (TTM)
−$565.17M
Shares outstanding
165.6M
Dividend yield
—
52-week range
$217.51 – $261.00

Ionis Pharmaceuticals's market cap is $40.47B, based on a share price of $244.31 and 165.6M shares outstanding as of Jun 30, 2026.

Financials

Ionis Pharmaceuticals reported revenue of $943.71M for fiscal 2025, up 33.83% from fiscal 2024.

Ionis Pharmaceuticals reported a net loss of $381.39M in fiscal 2025.

Annual revenue

FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Annual revenue by fiscal year; the table below lists the values.
Ionis Pharmaceuticals annual financials by fiscal year, from SEC filings
Fiscal yearRevenueGrowthNet incomeNet marginEPS (diluted)Free cash flow
FY2025ended Dec 31, 2025$943.71M+33.8%−$381.39M−40.4%−$2.38−$320.03M
FY2024ended Dec 31, 2024$705.14M−10.5%−$453.90M−64.4%−$3.04−$546.23M
FY2023ended Dec 31, 2023$787.65M+34.1%−$366.29M−46.5%−$2.56−$331.32M
FY2022ended Dec 31, 2022$587.37M−27.5%−$269.72M−45.9%−$1.90−$290.09M
FY2021ended Dec 31, 2021$810.46M+11.1%−$28.60M−3.5%−$0.20$18.84M
FY2020ended Dec 31, 2020$729.26M−35.0%−$444.26M−60.9%−$3.18$772.00K
FY2019ended Dec 31, 2019$1.12B+87.2%$278.14M24.8%$1.90$314.72M
FY2018ended Dec 31, 2018$599.67M+18.1%$273.74M45.7%$2.07$589.30M
FY2017ended Dec 31, 2017$507.67M+46.5%$346.00K0.1%$0.15$139.39M
FY2016ended Dec 31, 2016$346.62M—−$60.40M−17.4%−$0.50−$119.21M
Ionis Pharmaceuticals quarterly results
QuarterRevenueNet incomeEPS (diluted)
Q2 FY2026ended Jun 30, 2026$267.95M−$114.65M−$0.69
Q1 FY2026ended Mar 31, 2026$246.09M−$92.53M−$0.56
Q4 FY2025ended Dec 31, 2025$203.33M−$229.39M−$1.41
Q3 FY2025ended Sep 30, 2025$156.72M−$128.61M−$0.80
Q2 FY2025ended Jun 30, 2025$452.05M$123.55M$0.70
Q1 FY2025ended Mar 31, 2025$131.61M−$146.94M−$0.93
Q4 FY2024ended Dec 31, 2024$226.58M−$104.35M−$0.66
Q3 FY2024ended Sep 30, 2024$133.81M−$140.48M−$0.95

Company profile

Name
Ionis Pharmaceuticals, Inc.
Ticker
IONS
Exchange
NASDAQ
Industry (SEC SIC)
Pharmaceutical Preparations
Headquarters
2855 Gazelle Court, Carlsbad, CA 92010
Incorporated in
CA
Fiscal year ends
December
SEC CIK
0000874015

Recent SEC filings

Frequently asked questions

What is Ionis Pharmaceuticals's stock price?

Ionis Pharmaceuticals (IONS) closed at $244.31 on Oct 9, 2026, up 1.05% from the previous close of $241.77.

What is Ionis Pharmaceuticals's market cap?

Ionis Pharmaceuticals's market cap is $40.47B, based on a share price of $244.31 and 165.6M shares outstanding as of Jun 30, 2026.

How much revenue does Ionis Pharmaceuticals make?

Ionis Pharmaceuticals reported revenue of $943.71M for fiscal 2025, up 33.83% from fiscal 2024.

Does Ionis Pharmaceuticals pay a dividend?

Ionis Pharmaceuticals's recent filings report no dividends declared over the last four quarters.

Sources and methodology

Fundamentals come from Ionis Pharmaceuticals, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures